Previous 10 | Next 10 |
The NORA study, presented as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress , demonstrates that niraparib maintenance treatment resulted in a 68 % reduction in the risk of disease progression or death in the ove...
A 94-subject Phase 2 clinical trial, PODIUM-202 , evaluating Incyte's (NASDAQ: INCY ) PD-1 inhibitor retifanlimab (formerly INCMGA0012) in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemo showed a tr...
Zai Lab (NASDAQ: ZLAB ) announces the launch of its Hong Kong public offering of 10,564,050 new ordinary shares, which includes 771,700 new shares in Hong Kong and 9,792,350 in the international offering. More news on: Zai Lab Limited, Healthcare stocks news, IPO News, Re...
SHANGHAI and SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB), an innovative commercial stage biopharmaceutical company, today announced the launch of its Hong Kong public offering (the “Hong Kong...
Deals and Financings Baidu (BIDU), one of China's major internet/AI companies, is talking with investors about raising $2 billion to fund a new China drug development and diagnostics company. It believes the $2 billion fundraising will take two years to complete. The new company plans to...
- ZEJULA is the only PARP inhibitor approved as monotherapy for all-comer patients in the first-line and recurrent maintenance treatment settings regardless of biomarker status - ZEJULA was recommended as a monotherapy first-line maintenance treatment for women with platinum-responsive...
SHANGHAI and SAN FRANCISCO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that detailed clinical data from the NORA Phase 3 study of niraparib have been accepted as a lat...
SHANGHAI and SAN FRANCISCO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that Dr. Samantha Du, Founder, Chairwoman and Chief Executive Officer of Zai Lab, will be present...
Image source: The Motley Fool. Zai Lab Limited (NASDAQ: ZLAB) Q2 2020 Earnings Call Aug 13, 2020 , 8:00 a.m. ET Operator Continue reading
Zai Lab Limited (ZLAB) Q2 2020 Earnings Conference Call August 13, 2020 8:00 AM ET Company Participants Billy Cho – Chief Financial Officer Samantha Du – Founder, Chair Person and Chief Executive Officer Tao Fu – President and Chief Operating Officer Jonath...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...